A potential new role for the proto-oncogene PBF in endocrine cancer as a regulator of endothelial cells and angiogenesis

The proto-oncogene pituitary tumor-transforming gene (PTTG)-binding factor (PBF/PTTG1IP) has been implicated in multiple malignancies, including thyroid cancer, where PBF overexpression is associated with tumour progression and poorer prognosis. PBF promotes several tumourigenic processes such as cell migration and invasion and, although its primary function remains unclear, a physiological role for PBF in cell motility has recently been identified. PBF is ubiquitously expressed and whole genome transcriptomics studies in normal tissue suggest that the highest PBF expression is within blood vessels. Additionally, single cell transcriptomics data from numerous tissues including ovary, lung, liver and testes show that PBF expression is highest in endothelial cells within these tissues. However, the role of PBF in endothelial cells is completely uncharacterised. Given the critical role of angiogenesis in tumour growth and metastasis we hypothesised that PBF is a novel regulator of angiogenesis via induction of endothelial cell motility. Our preliminary studies have utilised siRNA-mediated PBF knockdown in human umbilical cord vein endothelial cells (HUVECs). Interestingly, we observed that reduced PBF expression increased endothelial cell tube formation in 2D Matrigel tube formation assays, suggesting that PBF may negatively regulate angiogenesis. This assay mimics multiple steps of angiogenesis including cell differentiation, reorganisation, and adhesion. However, intriguingly no difference was found in the rate of wound recovery when PBF levels were reduced in scratch wound assays indicating that PBF’s effects may be specific to responding to angiogenic stimuli response rather than general endothelial cell motility. These findings suggest that PBF could function as an angiogenic regulator in endothelial cells offering new insights into its role in vascular biology. This study represents the first steps towards uncovering the function of PBF in endothelial cells and may reveal a role for PBF in endothelial-driven processes linked to endocrine malignancy.

Authors

Publication Details

Journal
Endocrine Abstracts
Published
2025-02-19
DOI
https://doi.org/10.1530/endoabs.109.p94
Primary Topic
Cancer, Lipids, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A potential new role for the proto-oncogene PBF in endocrine cancer as a regulator of endothelial cells and angiogenesis

Aditi Hariharan, Victoria L. Heath, Katie Brookes, Selvambigai Manivannan et al.
Endocrine Abstracts
Cancer, Lipids, and Metabolism
article

A potential new role for the proto-oncogene PBF in endocrine cancer as a regulator of endothelial cells and angiogenesis

Aditi Hariharan, Victoria L. Heath, Katie Brookes, Selvambigai Manivannan, Siegelaar Sarah E., Naitala Andrew R, Ronchi Cristina l., M J, Davina Banga
article en

Abstract

The proto-oncogene pituitary tumor-transforming gene (PTTG)-binding factor (PBF/PTTG1IP) has been implicated in multiple malignancies, including thyroid cancer, where PBF overexpression is associated with tumour progression and poorer prognosis. PBF promotes several tumourigenic processes such as cell migration and invasion and, although its primary function remains unclear, a physiological role for PBF in cell motility has recently been identified. PBF is ubiquitously expressed and whole genome transcriptomics studies in normal tissue suggest that the highest PBF expression is within blood vessels. Additionally, single cell transcriptomics data from numerous tissues including ovary, lung, liver and testes show that PBF expression is highest in endothelial cells within these tissues. However, the role of PBF in endothelial cells is completely uncharacterised. Given the critical role of angiogenesis in tumour growth and metastasis we hypothesised that PBF is a novel regulator of angiogenesis via induction of endothelial cell motility. Our preliminary studies have utilised siRNA-mediated PBF knockdown in human umbilical cord vein endothelial cells (HUVECs). Interestingly, we observed that reduced PBF expression increased endothelial cell tube formation in 2D Matrigel tube formation assays, suggesting that PBF may negatively regulate angiogenesis. This assay mimics multiple steps of angiogenesis including cell differentiation, reorganisation, and adhesion. However, intriguingly no difference was found in the rate of wound recovery when PBF levels were reduced in scratch wound assays indicating that PBF’s effects may be specific to responding to angiogenic stimuli response rather than general endothelial cell motility. These findings suggest that PBF could function as an angiogenic regulator in endothelial cells offering new insights into its role in vascular biology. This study represents the first steps towards uncovering the function of PBF in endothelial cells and may reveal a role for PBF in endothelial-driven processes linked to endocrine malignancy.

Endocrine Abstracts
Good health and well-being
Openalex Percentile: Top 96%
Cancer, Lipids, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.